Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer (CYCLONE 1)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04408924 |
Recruitment Status :
Active, not recruiting
First Posted : May 29, 2020
Last Update Posted : June 23, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Castration-Resistant Prostate Cancer | Drug: Abemaciclib | Phase 2 |
Expanded Access : An investigational treatment associated with this study is available outside the clinical trial. More info ...
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy |
Actual Study Start Date : | January 20, 2021 |
Actual Primary Completion Date : | April 27, 2022 |
Estimated Study Completion Date : | August 22, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Abemaciclib
Abemaciclib given orally.
|
Drug: Abemaciclib
Administered orally
Other Name: LY2835219 |
- Objective Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR) [ Time Frame: Baseline to Objective Radiographic Soft Tissue Disease Progression (Estimated up to 12 Months) ]ORR: Percentage of Participants with Best Response of CR or PR
- Radiographic Progression-Free Survival (rPFS) [ Time Frame: Baseline to Radiographic Disease Progression or Death from Any Cause (Estimated up to 12 Months) ]rPFS
- Overall Survival (OS) [ Time Frame: Baseline to Date of Death Due to Any Cause (Estimated up to 24 Months) ]OS
- Duration of Response (DOR) [ Time Frame: Date of First Documented CR or PR to Date of Radiographic Disease Progression or Death from Any Cause (Estimated up to 12 Months) ]DoR
- Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), CR or PR [ Time Frame: Baseline to Radiographic Soft Tissue Disease Progression (Estimated up to 12 Months) ]DCR: Percentage of participants who exhibit SD, CR or PR
- Prostate Specific Antigen (PSA) Response Rate [ Time Frame: Baseline to Date of Treatment Discontinuation (Estimated up to 12 Months) ]PSA Response Rate: Percentage of Participants with a PSA Decrease of at Least 50% from Baseline
- Time to PSA Progression [ Time Frame: Baseline to the Date of First Observation of PSA Progression (Estimated up to 12 Months) ]Time to PSA Progression
- Time to Symptomatic Progression [ Time Frame: Baseline to the Date of First Documented Symptomatic Progression (Estimated up to 12 Months) ]Time to Symptomatic Progression
- Patient-Reported Outcomes (PRO) [ Time Frame: Baseline to End of Study (Estimated up to 12 Months) ]Patient-reported tolerability, including select symptomatic adverse events (from the PRO-Common Terminology Criteria for Adverse Events item library) and overall side-effect burden (item GP5 of the Functional Assessment of Cancer Therapy Tool General form (FACT-G))
- Pharmacokinetics (PK): Mean Steady State Concentration of Abemaciclib and its Metabolites [ Time Frame: Predose Cycle 1 Day 15 through Predose Cycle 3 Day 1 (28 Day Cycles) ]PK: Mean Steady State Concentration of Abemaciclib and its Metabolites
- Percentage of Ki-67 Positive Cells by Immunohistochemistry (IHC) [ Time Frame: Baseline ]Percentage of Ki-67 positive cells by IHC

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participant must have metastatic prostate cancer for which castration (medical or surgical) is no longer effective (castration-resistant).
- Participant must have disease spread to soft tissue that is measurable.
- Participant must have documented evidence of progressive disease by PSA test or imaging.
- Participant must have previously received at least one of the following treatment: abiraterone acetate, apalutamide, darolutamide or enzalutamide.
- Participant must have previously received chemotherapy with docetaxel and cabazitaxel.
- Participant must be willing and amenable to undergo a biopsy of tumor tissue (or able to provide adequate archived tumor tissue sample) and to provide blood for research.
- Participant must have good physical functioning ability and adequate organ function.
Exclusion Criteria:
- Participant must not have received more than 3 therapy regimens for metastatic castration-resistant prostate cancer (NOTE: GnRHa, first-generation antiandrogens (flutamide, nilutamide, or bicalutamide), diethylstilbestrol (DES) (or other estrogens), corticosteroids, ketoconazole, and bone loss-prevention will not count as systemic therapy regimens.
- Participants must not have previously received abemaciclib or any cyclin-dependent kinase (CDK)4 and/or CDK6 inhibitors.
- Participants must not have serious and/or uncontrolled preexisting medical condition(s) including but not limited to severe renal impairment, severe hepatic impairment, interstitial lung disease (ILD)/pneumonitis, severe dyspnea at rest or requiring oxygen therapy or other serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.
- Participants must not have, or suspected to have, brain metastasis.
- Participants must not have untreated spinal cord compression, evidence of spinal metastases with risk of spinal compression or structurally unstable bone lesions suggesting impending fracture.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04408924
United States, Utah | |
University of Utah - Huntsman Cancer Institute | |
Salt Lake City, Utah, United States, 84112 | |
United States, Washington | |
Seattle Cancer Care Alliance | |
Seattle, Washington, United States, 98109 | |
France | |
Centre Leon Berard | |
Lyon Cedex 08, France, 69373 | |
Institut Paoli-Calmettes | |
Marseille, France, 13273 | |
Hopital Europeen Georges Pompidou | |
Paris, France, 75015 | |
Institut Claudius Regaud | |
Toulouse cedex 9, France, 31059 | |
Gustave Roussy | |
Villejuif Cedex, France, 94805 | |
Spain | |
Institut Catala d'Oncologia | |
L'Hospitalet de Llobregat, Barcelona, Spain, 08907 | |
Corporacion Sanitaria Parc Tauli | |
Sabadell, Barcelona, Spain, 08208 | |
Hospital de la Santa Creu i Sant Pau | |
Barcelona, Spain, 08025 | |
Hospital Universitari Vall d'Hebron | |
Barcelona, Spain, 08035 | |
Hospital General Universitario Gregorio Maranon | |
Madrid, Spain, 28007 | |
Hospital Universitario Ramon y Cajal | |
Madrid, Spain, 28034 | |
Hospital Universitario 12 de Octubre | |
Madrid, Spain, 28041 |
Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
Responsible Party: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT04408924 |
Other Study ID Numbers: |
17583 I3Y-MC-JPCY ( Other Identifier: Eli Lilly and Company ) 2020-000290-24 ( EudraCT Number ) |
First Posted: | May 29, 2020 Key Record Dates |
Last Update Posted: | June 23, 2022 |
Last Verified: | June 9, 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Clinical Study Report (CSR) |
Time Frame: | Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting. |
Access Criteria: | A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement. |
URL: | https://vivli.org/ |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
mCRPC CDK4 CDK6 CDK4/6 CDK4&6 inhibitor |
CDK4/6 inhibitor LY2835219 CYCLONE 1 CYCLONE1 |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms |
Neoplasms by Site Neoplasms Prostatic Diseases |